AstraZeneca withdrawing it COVID vaccine from the market has nothing to do with blood clots.
Academic rigour, journalistic flair
Articles on AstraZeneca vaccine
Displaying 1 - 20 of 155 articles
A mathematician explains the important difference between absolute risk and relative risk.
On the horizon: A new omicron-focused version of the Moderna vaccine that may offer longer protection and a stronger immune response.
Despite being an excellent vaccine, the use of AstraZeneca in the UK has declined over the course of the COVID pandemic.
Properly engaged and monitored, Nigeria’s private sector can do more in COVID vaccination exercise.
Viral vectors are modified viruses that trigger an immune response without causing infection. The vector that’s used in several COVID-19 vaccines was created decades ago by Canadian Frank Graham.
Before the pandemic, the public perceived science as infallible and inaccessible. But the opening up of research to the general public has changed that perception.
You’ll read lots of different figures on this — six months, eight months, more — and that’s because the research is ongoing. We don’t yet have a concrete answer.
As we continue to roll out COVID-19 vaccines around the world, we’re learning people who are immunocompromised aren’t necessarily protected as well from the first two doses.
Some countries have started administering third doses of COVID vaccines, or booster shots. But we’re still learning about how long immunity lasts from the first two shots.
Not vaccinating children means living with the knowledge we haven’t done everything possible to ensure they don’t transmit COVID to more vulnerable people.
The federal government has announced the Pfizer vaccine will be available to all Australians from August 30. Though there may well be long waits.
What do you need to weigh up when working out whether to get the AstraZeneca vaccine? Here’s what the evidence says.
To paraphrase a legendary golfing saying, the harder you work, the luckier you get.
Vaccinating a population requires a proactive approach to health promotion and community preparedness.
Weeks do matter when it comes to the Delta strain. With Australia still heavily reliant on the AstraZeneca vaccine, for now it makes sense to reduce the time between the first and second jab.
The messages people under 60 have been getting about the AstraZeneca vaccine this week have been confusing, to say the least. Experts say to consider the risks and benefits. But how do you do this?
A study at the University of Oxford has looked at what happens when people receive one dose of AstraZeneca one dose of Pfizer.
At the moment, the scheme only applies to health practitioners, not patients.
While Pfizer is still the preferred vaccine for under 40s, those who don’t want to wait can now talk to their GP about getting an AstraZeneca shot. But what risks and benefits do you need to weigh up?
Job Board
-
Professor of Indigenous Cultural and Creative Industries (Identified)
-
Communications Director
-
Associate Director, Post-Award, RGCF
-
University Relations Manager
-
2024 Vice-Chancellor's Research Fellowships
Top contributors
-
Professorial Fellow, University of Canberra
-
Senior Research Fellow in Global Health, University of Southampton
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Medicine, University of East Anglia
-
Director of the Digital Health Enterprise Zone (DHEZ), University of Bradford, Professor of Health Service Operations, University of Bradford
-
Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Deputy Director of the HUMLOG (Humanitarian Logistics and Supply Chain Management Research) Institute, Hanken School of Economics
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
General Practitioner, PhD Candidate, Bond University
-
Professor of Immunology, RMIT University
-
Chair in Epidemiology, Deakin University
-
Principal Lecturer, Microbiology and Biomedical Science Practice, Fellow of the Institute of Biomedical Science, University of Brighton
-
Professor of Intellectual Property Law, Queen Mary University of London
-
Postdoctoral Research Fellow, RMIT University
